vs
ACADIA PHARMACEUTICALS INC（ACAD）与亚什兰（ASH）财务数据对比。点击上方公司名可切换其他公司
亚什兰的季度营收约是ACADIA PHARMACEUTICALS INC的1.4倍（$386.0M vs $284.0M），ACADIA PHARMACEUTICALS INC净利率更高（96.3% vs -3.1%，领先99.4%），ACADIA PHARMACEUTICALS INC同比增速更快（9.4% vs -4.7%），过去两年ACADIA PHARMACEUTICALS INC的营收复合增速更高（17.5% vs -18.1%）
阿卡迪亚制药是一家总部位于美国加利福尼亚州圣地亚哥德尔马地区的生物制药企业，专注于中枢神经系统相关疾病治疗药物的研发、生产与商业化，致力于为全球患者提供创新的临床治疗方案。
亚什兰是一家总部位于美国特拉华州威尔明顿的化工企业，1924年始创于肯塔基州亚什兰市，最初以炼油业务起家，1994年迁至现总部。公司拥有多个业务板块，覆盖化工中间体与溶剂、复合材料、工业特种化学品、个人及家居护理、制药、食品饮料以及农业相关领域，2017年之前曾是胜牌润滑油的主要生产商。
ACAD vs ASH — 直观对比
营收规模更大
ASH
是对方的1.4倍
$284.0M
营收增速更快
ACAD
高出14.1%
-4.7%
净利率更高
ACAD
高出99.4%
-3.1%
两年增速更快
ACAD
近两年复合增速
-18.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $284.0M | $386.0M |
| 净利润 | $273.6M | $-12.0M |
| 毛利率 | 90.8% | 27.2% |
| 营业利润率 | 6.1% | -1.6% |
| 净利率 | 96.3% | -3.1% |
| 营收同比 | 9.4% | -4.7% |
| 净利润同比 | 90.3% | 92.7% |
| 每股收益（稀释后） | $1.61 | $-0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACADASH
| Q4 25 | $284.0M | $386.0M | ||
| Q3 25 | $278.6M | $477.0M | ||
| Q2 25 | $264.6M | $463.0M | ||
| Q1 25 | $244.3M | $479.0M | ||
| Q4 24 | $259.6M | $405.0M | ||
| Q3 24 | $250.4M | $521.0M | ||
| Q2 24 | $242.0M | $544.0M | ||
| Q1 24 | $205.8M | $575.0M |
净利润ACADASH
| Q4 25 | $273.6M | $-12.0M | ||
| Q3 25 | $71.8M | $31.0M | ||
| Q2 25 | $26.7M | $-742.0M | ||
| Q1 25 | $19.0M | $31.0M | ||
| Q4 24 | $143.7M | $-165.0M | ||
| Q3 24 | $32.8M | $17.0M | ||
| Q2 24 | $33.4M | $6.0M | ||
| Q1 24 | $16.6M | $120.0M |
毛利率ACADASH
| Q4 25 | 90.8% | 27.2% | ||
| Q3 25 | 92.2% | 33.3% | ||
| Q2 25 | 92.2% | 28.5% | ||
| Q1 25 | 91.7% | 30.7% | ||
| Q4 24 | 91.6% | 27.4% | ||
| Q3 24 | 92.5% | 33.2% | ||
| Q2 24 | 92.5% | 34.2% | ||
| Q1 24 | 88.8% | 28.0% |
营业利润率ACADASH
| Q4 25 | 6.1% | -1.6% | ||
| Q3 25 | 12.8% | 12.8% | ||
| Q2 25 | 12.2% | -152.9% | ||
| Q1 25 | 7.9% | 10.6% | ||
| Q4 24 | 59.1% | -44.2% | ||
| Q3 24 | 12.6% | 6.1% | ||
| Q2 24 | 12.6% | -11.2% | ||
| Q1 24 | 7.4% | 3.7% |
净利率ACADASH
| Q4 25 | 96.3% | -3.1% | ||
| Q3 25 | 25.8% | 6.5% | ||
| Q2 25 | 10.1% | -160.3% | ||
| Q1 25 | 7.8% | 6.5% | ||
| Q4 24 | 55.4% | -40.7% | ||
| Q3 24 | 13.1% | 3.3% | ||
| Q2 24 | 13.8% | 1.1% | ||
| Q1 24 | 8.0% | 20.9% |
每股收益（稀释后）ACADASH
| Q4 25 | $1.61 | $-0.26 | ||
| Q3 25 | $0.42 | $0.83 | ||
| Q2 25 | $0.16 | $-16.21 | ||
| Q1 25 | $0.11 | $0.65 | ||
| Q4 24 | $0.86 | $-3.50 | ||
| Q3 24 | $0.20 | $0.34 | ||
| Q2 24 | $0.20 | $0.12 | ||
| Q1 24 | $0.10 | $2.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $177.7M | $304.0M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $1.2B | $1.9B |
| 总资产 | $1.6B | $4.5B |
| 负债/权益比越低杠杆越低 | — | 0.74× |
8季度趋势，按日历期对齐
现金及短期投资ACADASH
| Q4 25 | $177.7M | $304.0M | ||
| Q3 25 | $258.0M | $215.0M | ||
| Q2 25 | $253.6M | $207.0M | ||
| Q1 25 | $217.7M | $168.0M | ||
| Q4 24 | $319.6M | $219.0M | ||
| Q3 24 | $155.1M | $300.0M | ||
| Q2 24 | $177.1M | $399.0M | ||
| Q1 24 | $204.7M | $439.0M |
总债务ACADASH
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.3B | ||
| Q1 24 | — | $1.3B |
股东权益ACADASH
| Q4 25 | $1.2B | $1.9B | ||
| Q3 25 | $917.3M | $1.9B | ||
| Q2 25 | $822.4M | $1.9B | ||
| Q1 25 | $765.2M | $2.6B | ||
| Q4 24 | $732.8M | $2.6B | ||
| Q3 24 | $577.2M | $2.9B | ||
| Q2 24 | $516.7M | $3.0B | ||
| Q1 24 | $464.0M | $3.1B |
总资产ACADASH
| Q4 25 | $1.6B | $4.5B | ||
| Q3 25 | $1.3B | $4.6B | ||
| Q2 25 | $1.2B | $4.6B | ||
| Q1 25 | $1.1B | $5.2B | ||
| Q4 24 | $1.2B | $5.2B | ||
| Q3 24 | $976.9M | $5.6B | ||
| Q2 24 | $914.1M | $5.7B | ||
| Q1 24 | $855.1M | $5.9B |
负债/权益比ACADASH
| Q4 25 | — | 0.74× | ||
| Q3 25 | — | 0.73× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 0.52× | ||
| Q4 24 | — | 0.51× | ||
| Q3 24 | — | 0.47× | ||
| Q2 24 | — | 0.45× | ||
| Q1 24 | — | 0.42× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-48.7M | $125.0M |
| 自由现金流经营现金流 - 资本支出 | — | $111.0M |
| 自由现金流率自由现金流/营收 | — | 28.8% |
| 资本支出强度资本支出/营收 | — | 3.6% |
| 现金转化率经营现金流/净利润 | -0.18× | — |
| 过去12个月自由现金流最近4个季度 | — | $200.0M |
8季度趋势，按日历期对齐
经营现金流ACADASH
| Q4 25 | $-48.7M | $125.0M | ||
| Q3 25 | $74.3M | $40.0M | ||
| Q2 25 | $64.0M | $115.0M | ||
| Q1 25 | $20.3M | $9.0M | ||
| Q4 24 | $40.4M | $-30.0M | ||
| Q3 24 | $63.2M | $80.0M | ||
| Q2 24 | $25.0M | $127.0M | ||
| Q1 24 | $29.1M | $54.0M |
自由现金流ACADASH
| Q4 25 | — | $111.0M | ||
| Q3 25 | $73.9M | $6.0M | ||
| Q2 25 | — | $95.0M | ||
| Q1 25 | — | $-12.0M | ||
| Q4 24 | — | $-53.0M | ||
| Q3 24 | $63.2M | $42.0M | ||
| Q2 24 | — | $98.0M | ||
| Q1 24 | — | $20.0M |
自由现金流率ACADASH
| Q4 25 | — | 28.8% | ||
| Q3 25 | 26.5% | 1.3% | ||
| Q2 25 | — | 20.5% | ||
| Q1 25 | — | -2.5% | ||
| Q4 24 | — | -13.1% | ||
| Q3 24 | 25.2% | 8.1% | ||
| Q2 24 | — | 18.0% | ||
| Q1 24 | — | 3.5% |
资本支出强度ACADASH
| Q4 25 | — | 3.6% | ||
| Q3 25 | 0.1% | 7.1% | ||
| Q2 25 | — | 4.3% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | 0.0% | 7.3% | ||
| Q2 24 | — | 5.3% | ||
| Q1 24 | — | 5.9% |
现金转化率ACADASH
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | 1.29× | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | 0.29× | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | 4.71× | ||
| Q2 24 | 0.75× | 21.17× | ||
| Q1 24 | 1.76× | 0.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
ASH
| Personal Care And Household | $123.0M | 32% |
| Other | $120.0M | 31% |
| Specialty Additives | $36.0M | 9% |
| Intermediates And Solvents | $31.0M | 8% |
| Personal Care | $30.0M | 8% |
| Life Sciences | $27.0M | 7% |
| Intermediates | $19.0M | 5% |
